<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03539393</url>
  </required_header>
  <id_info>
    <org_study_id>TV48125-CNS-80005</org_study_id>
    <nct_id>NCT03539393</nct_id>
  </id_info>
  <brief_title>Expanded Access Program for Patients With Migraine</brief_title>
  <official_title>A Fremanezumab (TEV-48125) Expanded Access Program for Patients With Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Branded Pharmaceutical Products R&amp;D, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <brief_summary>
    <textblock>
      This expanded access program is designed to make fremanezumab available to patients with EM
      or CM who have successfully completed (per protocol) Teva-sponsored Study TV48125-CNS-30051
      or TV48125-CNS-30068 (&quot;prior studies&quot;) until fremanezumab becomes commercially available in
      their country.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fremanezumab is indicated for patient suffering from Episodic or Chronic Migraine.

      Patients interested in received expanded access to Fremanezumab must meet the following
      conditions:

        1. Have participated in, and successfully completed, one of the two clinical studies
           TV48125-CNS-30051 (HALO) or TV48125-CNS-30068 (FOCUS)

        2. Participated from one of the following countries:

             1. For HALO: Canada, Czech Republic, Spain or Finland

             2. For FOCUS: Czech Republic, Spain, Finland, Germany, Sweden, Denmark, Netherlands,
                Italy, France or Belgium Eligible patients should contact their study physician to
                request expanded access.
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Migraine</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fremanezumab</intervention_name>
    <description>quarterly 675 mg dose (3 subcutaneous [SC] injections of 225 mg each).</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient must have completed Teva-sponsored Study TV48125-CNS-30051 or
             TV48125-CNS-30068 as defined in the study protocol and without major protocol
             violations.

          -  The patient is unable to obtain fremanezumab under another Investigational New Drug or
             through a clinical study.

          -  In the opinion and clinical judgement of the treating physician, the risk/benefit for
             the patient supports continuing treatment with fremanezumab.

          -  The treating physician determined that there is no other comparable or satisfactory
             therapy available to treat the patient.

          -  Women may be included only if they have a negative serum beta-human chorionic
             gonadotropin test at enrollment, are sterile, or postmenopausal.

          -  Women of childbearing potential (WOCBP) whose male partners are potentially fertile
             (ie, no vasectomy) must use highly effective birth control methods for the duration of
             their participation in the program and for 7.5 months after discontinuation of
             fremanezumab.

          -  Men must be sterile, or if they are potentially fertile/reproductively competent (not
             surgically [eg, vasectomy] or congenitally sterile) and their female partners are of
             childbearing potential, must use, together with their female partners, acceptable
             birth control methods for the duration of their participation in the program and for
             7.5 months after discontinuation of fremanezumab.

          -  Additional criteria apply, please contact the investigator for more information

        Exclusion Criteria:

          -  The patient had any finding on their last available test that, in the judgment of the
             treating physician, is a clinically significant abnormality, including hematology
             values, serum chemistry, coagulation tests, or urinalysis (abnormal tests may be
             repeated for confirmation).

          -  The patient is a pregnant or lactating/nursing female or plans to become pregnant
             during the program or for 7.5 months after discontinuing treatment.

          -  The patient had any finding in their last available 12-lead electrocardiogram
             considered clinically significant in the judgment of the treating physician.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Teva Investigational Site 37096</name>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 37093</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 37095</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 37094</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 11151</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 11152</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <zip>N7T 4X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 11149</name>
      <address>
        <city>Calgary</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 54170</name>
      <address>
        <city>Brno</city>
        <zip>602 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 54181</name>
      <address>
        <city>Ostrava-Moravska</city>
        <zip>702 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 54171</name>
      <address>
        <city>Pardubice</city>
        <zip>530 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 54167</name>
      <address>
        <city>Prague 6</city>
        <zip>160 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 54182</name>
      <address>
        <city>Prague 8</city>
        <zip>186 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 54172</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 54173</name>
      <address>
        <city>Rychnov nad Kneznou</city>
        <zip>516 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 30206</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 30211</name>
      <address>
        <city>Rome</city>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 31247</name>
      <address>
        <city>Barcelona</city>
        <zip>08029</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 31240</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 31249</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 31238</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 42059</name>
      <address>
        <city>Stockholm</city>
        <zip>112 81</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34239</name>
      <address>
        <city>Hull</city>
        <zip>HU3 2JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34237</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 15, 2018</study_first_submitted>
  <study_first_submitted_qc>May 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2018</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

